KNSA vs PTGX: stock comparison and AI forecast
Kiniksa Pharmaceuticals International, Plc (KNSA) and Protagonist Therapeutics, Inc (PTGX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
KNSA Kiniksa Pharmaceuticals International, Plc
- Price
- $98.76 +69.2% · 6M
- Market Cap
- $7.76B
- P/E Ratio
- 91.5x
- Size
- mid-cap
- AI Forecast
PTGX Protagonist Therapeutics, Inc
- Price
- $135.90 +31.3% · 6M
- Market Cap
- $8.79B
- P/E Ratio
- 34.6x
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- PTGX is 1.1 times larger than KNSA by market capitalization ($8.79B against $7.76B).
- PTGX trades at 34.6 times trailing earnings, KNSA at 91.5 times.
- Over the last six months KNSA returned +69.2% and PTGX +31.3%.
- PTGX turns 155.8% of its revenue into net income, against 11.6% for KNSA.
- KNSA carries 0.38 times debt per unit of equity, against 0.06 times for PTGX.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | KNSA | PTGX |
|---|---|---|
| Market Cap | $7.76B | $8.79B |
| P/E Ratio | 91.45x | 34.58x |
| P/B Ratio | 10.93x | 8.11x |
| EPS | $1.08 | $3.93 |
| Book Value/Share | $9.04 | $16.77 |
| Revenue/Share | $12.04 | $3.39 |
| FCF/Share | $2.51 | $1.69 |
Profitability & Margins
| Metric | KNSA | PTGX |
|---|---|---|
| ROE | 15.4% | 31.6% |
| ROA | 11.1% | 29.9% |
| ROIC | 16.5% | 29.6% |
| Gross Margin | 90.2% | – |
| Operating Margin | 13.8% | 147.1% |
| Net Margin | 11.6% | 155.8% |
| EBT Margin | 15.4% | 158.4% |
| Tax Rate | 25.0% | 2.3% |
Financial Health
| Metric | KNSA | PTGX |
|---|---|---|
| Current Ratio | 3.91x | 19.85x |
| Quick Ratio | 3.35x | – |
| D/E Ratio | 0.38x | 0.06x |
| Financial Leverage | 1.38x | 1.06x |
| Working Capital | $558M | $1.05B |
Cash Flow
| Metric | KNSA | PTGX |
|---|---|---|
| Operating Cash Flow | $199M | $110M |
| Free Cash Flow | $197M | $109M |
| Capital Spending | -$2M | -$760K |
| OCF Growth YoY | 93.3% | 67.9% |
| FCF Growth YoY | 93.8% | 71.3% |
| FCF/Sales | 20.9% | 49.7% |
| CapEx/Sales | 0.2% | 0.3% |
Operational Efficiency
| Metric | KNSA | PTGX |
|---|---|---|
| Asset Turnover | 0.96x | 0.19x |
| Receivables Turnover | 30.7x | – |
| Inventory Turnover | 0.9x | – |
| Fixed Assets Turnover | 383.9x | 66.1x |
| Days Sales Outstanding | 12 days | – |
| Days Inventory | 424 days | – |
| Payables Period | 16 days | – |
| Cash Conversion Cycle | 419 days | – |
Income Statement
| Metric | KNSA | PTGX |
|---|---|---|
| Total Revenue | $946M | $220M |
| Operating Income | $130M | $323M |
| Net Income | $110M | $342M |
| R&D Expense | $136M | $176M |
| SG&A Expense | $247M | – |
| Cost of Goods Sold | $93M | – |
Dividend & Shareholder Information
| Metric | KNSA | PTGX |
|---|---|---|
| Shares Outstanding | 79M | 65M |
| Net Income Growth | 205.1% | 645.5% |
| EPS Growth | – | 182.7% |
KNSA vs PTGX: stock comparison and AI forecast
Which is bigger, KNSA or PTGX?
PTGX is 1.1 times larger than KNSA by market capitalization ($8.79B against $7.76B).
Which is cheaper on earnings, KNSA or PTGX?
PTGX trades at 34.6 times trailing earnings, KNSA at 91.5 times.
Which stock performed better over the last six months, KNSA or PTGX?
Over the last six months KNSA returned +69.2% and PTGX +31.3%.
Which one does Intratio's AI model rank higher, KNSA or PTGX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.